The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

Kennedy Jr. was pressed to clarify his views on vaccines, abortion and public health priorities in the first of two senate ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other safe stocks to ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...

Johnson & Johnson’s Consumer Health segment reported a revenue of $14.6 billion in the Full-Year 2021. It is projected that, following the separation, Kenvue will generate sales in over 100 ...